Latest Insider Transactions at Invitae Corp (NVTA)
This section provides a real-time view of insider transactions for Invitae Corp (NVTA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Invitae Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Invitae Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 28
2022
|
Kimber D Lockhart Director |
BUY
Grant, award, or other acquisition
|
Direct |
32,100
+44.15%
|
-
|
|
Apr 28
2022
|
Geoffrey Crouse Director |
BUY
Grant, award, or other acquisition
|
Direct |
32,100
+34.91%
|
-
|
|
Apr 28
2022
|
Christine Marie Gorjanc Director |
BUY
Grant, award, or other acquisition
|
Direct |
32,100
+44.15%
|
-
|
|
Apr 28
2022
|
Chitra Nayak Director |
BUY
Grant, award, or other acquisition
|
Direct |
32,100
+44.15%
|
-
|
|
Apr 28
2022
|
Eric Aguiar Director |
BUY
Grant, award, or other acquisition
|
Direct |
43,400
+29.74%
|
-
|
|
Apr 09
2022
|
Kenneth D. Knight Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
225,000
+29.14%
|
-
|
|
Apr 09
2022
|
Robert F. Werner Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
135,815
+39.3%
|
-
|
|
Apr 09
2022
|
Thomas Brida |
BUY
Grant, award, or other acquisition
|
Direct |
168,511
+29.73%
|
-
|
|
Apr 09
2022
|
Robert L Nussbaum Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
168,511
+29.14%
|
-
|
|
Apr 09
2022
|
Yafei Wen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
225,000
+38.37%
|
-
|
|
Mar 14
2022
|
Kenneth D. Knight Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,358
-0.73%
|
$14,148
$6.69 P/Share
|
|
Mar 14
2022
|
Robert L Nussbaum Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
19,588
-7.51%
|
$117,528
$6.69 P/Share
|
|
Mar 14
2022
|
Yafei Wen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,289
-2.35%
|
$19,734
$6.69 P/Share
|
|
Mar 14
2022
|
Thomas Brida |
SELL
Open market or private sale
|
Direct |
17,987
-7.26%
|
$107,922
$6.69 P/Share
|
|
Mar 14
2022
|
Sean E George Director |
SELL
Open market or private sale
|
Direct |
31,389
-3.72%
|
$188,334
$6.69 P/Share
|
|
Mar 12
2022
|
Kenneth D. Knight Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,705
+4.33%
|
-
|
|
Mar 12
2022
|
Robert L Nussbaum Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,705
+5.34%
|
-
|
|
Mar 12
2022
|
Yafei Wen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,705
+9.52%
|
-
|
|
Mar 12
2022
|
Thomas Brida |
BUY
Grant, award, or other acquisition
|
Direct |
14,705
+5.6%
|
-
|
|
Mar 12
2022
|
Sean E George Director |
BUY
Grant, award, or other acquisition
|
Direct |
44,117
+4.97%
|
-
|
|
Nov 11
2021
|
Robert L Nussbaum Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
29,675
-10.76%
|
$623,175
$21.89 P/Share
|
|
Nov 11
2021
|
Robert L Nussbaum Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
29,675
+5.24%
|
$296,750
$10.07 P/Share
|
|
Oct 22
2021
|
Sean E George Director |
SELL
Open market or private sale
|
Direct |
3,675
-0.46%
|
$102,900
$28.06 P/Share
|
|
Sep 27
2021
|
Sean E George Director |
BUY
Exercise of conversion of derivative security
|
Direct |
55,000
+3.25%
|
$330,000
$6.06 P/Share
|
|
Sep 22
2021
|
Sean E George Director |
SELL
Open market or private sale
|
Direct |
7,350
-0.97%
|
$227,850
$31.88 P/Share
|
|
Aug 19
2021
|
Robert F. Werner Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
15,337
-17.17%
|
$368,088
$24.86 P/Share
|
|
Aug 16
2021
|
Robert F. Werner Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
3,012
-3.26%
|
$75,300
$25.42 P/Share
|
|
Aug 16
2021
|
Sean E George Director |
SELL
Open market or private sale
|
Direct |
16,986
-2.2%
|
$424,650
$25.42 P/Share
|
|
Aug 16
2021
|
Thomas Brida |
SELL
Open market or private sale
|
Direct |
14,438
-5.85%
|
$360,950
$25.42 P/Share
|
|
Aug 16
2021
|
Robert L Nussbaum Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
21,231
-7.94%
|
$530,775
$25.42 P/Share
|
|
Jul 22
2021
|
Sean E George Director |
SELL
Open market or private sale
|
Direct |
3,675
-0.47%
|
$106,575
$29.39 P/Share
|
|
Jun 22
2021
|
Sean E George Director |
SELL
Open market or private sale
|
Direct |
3,675
-0.47%
|
$121,275
$33.02 P/Share
|
|
Jun 21
2021
|
Yafei Wen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
125,000
+50.0%
|
-
|
|
Jun 15
2021
|
Kenneth D. Knight Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
14,874
-4.58%
|
$446,220
$30.3 P/Share
|
|
Jun 14
2021
|
Sean E George Director |
SELL
Open market or private sale
|
Direct |
21,201
-2.65%
|
$657,231
$31.63 P/Share
|
|
Jun 14
2021
|
Robert L Nussbaum Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,910
-3.58%
|
$307,210
$31.63 P/Share
|
|
Jun 14
2021
|
Katherine Stueland Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
20,340
-4.43%
|
$630,540
$31.61 P/Share
|
|
Jun 14
2021
|
Shelly D Guyer Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,910
-3.93%
|
$307,210
$31.63 P/Share
|
|
Jun 14
2021
|
Thomas Brida |
SELL
Open market or private sale
|
Direct |
9,910
-3.86%
|
$307,210
$31.63 P/Share
|
|
May 20
2021
|
Sean E George Director |
SELL
Open market or private sale
|
Direct |
3,675
-0.46%
|
$102,900
$28.0 P/Share
|
|
May 20
2021
|
Robert F. Werner Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
7,116
-7.16%
|
$192,132
$27.62 P/Share
|
|
May 18
2021
|
Kenneth D. Knight Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
28,010
-7.94%
|
$756,270
$27.49 P/Share
|
|
May 18
2021
|
Robert F. Werner Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
6,653
-1.28%
|
-
|
|
May 18
2021
|
Shelly D Guyer Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,424
-1.34%
|
$92,448
$27.49 P/Share
|
|
May 06
2021
|
Shelly D Guyer Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,000
+9.56%
|
-
|
|
Apr 30
2021
|
Katherine Stueland Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
44,700
+16.01%
|
-
|
|
Apr 30
2021
|
Kenneth D. Knight Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
44,700
+11.25%
|
-
|
|
Apr 30
2021
|
Thomas Brida |
BUY
Grant, award, or other acquisition
|
Direct |
44,700
+14.84%
|
-
|
|
Apr 30
2021
|
Chitra Nayak Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,500
+50.0%
|
-
|
|
Apr 30
2021
|
Kimber D Lockhart Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,500
+50.0%
|
-
|